FREE 2-DAY SHIPPING ON ORDERS $200+

Blog

Tesamorelin Dosage Calculator and Chart: Units, Timing and Cycle Guide

Seven microtubes of daily tesamorelin portions in a rack in front of mixed and unmixed vials

Tesamorelin has carried three label doses since its 2010 approval, and the FDA treats all three as the same dose. The phase 3 trials gave 2mg a day (Egrifta label, FDA, 2010). The current Egrifta SV vial gives 1.4mg, and the newest version, Egrifta WR, gives 1.28mg. The two newer formulations absorb better, so a smaller number of milligrams reaches the same level in the blood.

That matters the moment a researcher holds a plain 10mg or 20mg vial of tesamorelin powder and a U-100 syringe. The milligrams have to become units, the units depend on how much water went in, and a vial that holds five doses at one setting holds twenty at another. Every figure below starts from the trials and ends on the syringe line.

Tesamorelin dosage calculator

Pick the vial, the water and the dose, and the calculator gives the units to draw on a U-100 insulin syringe. It opens on a 10mg vial with 2mL and a 2mg dose: 40 units.

Your inputs

Set the tesamorelin vial, the water added and the amount per draw.

Total tesamorelin mass in this vial, in milligrams.

Use the final solution volume in milliliters.

Target amount unit

Amount in one research sample. 1 mg = 1,000 mcg.

Updates as you typeView result ↓

Your calculation

Ready

U-100 syringe marking

—units

— mL / — µL

Syringe capacity U-100 scale

Schematic only. Check the graduations on your device.

Concentration
— mg/mL
Full samples per vial
—

— mg in each — mL sample

Starting values are examples, not recommended amounts. Results are rounded for display; sample counts exclude handling losses.

2mg, 1.4mg or 1.28mg: which number goes in the syringe

The two phase 3 trials, in 816 people, gave 2mg once a day under the skin of the abdomen for 26 weeks, then a 26-week extension. Visceral fat fell 18% and 14% at week 26, against +2% and −2% on placebo. The Egrifta SV label doses 1.4mg, drawn as 0.35mL from a 2mg vial mixed with 0.5mL of sterile water and used at once. The Egrifta WR label doses 1.28mg, drawn as 0.16mL (16 units) from an 11.6mg vial mixed with 1.3mL of bacteriostatic water, one vial covering 7 days. Both label doses match the blood exposure of the 2mg trial dose.

Two smaller trials used less. A 2005 dose-ranging trial gave 1mg or 2mg once a day for 12 weeks: IGF-1 rose 48% on 1mg and 65% on 2mg, and trunk fat fell 4.6% and 9.2%. A 2012 cognition trial gave 1mg 30 minutes before bedtime for 20 weeks to adults aged 55 to 87: IGF-1 rose 117% and body fat fell 7.4%.

The 2mg figure is the one with outcome data behind it. Both phase 3 trials, the 2005 dose-ranging study and the liver-fat trials all ran 2mg once a day (Falutz, New England Journal of Medicine, 2007). The 1.4mg and 1.28mg doses were approved later on a single finding: in healthy volunteers they produced the same blood exposure as 2mg of the original formulation (Egrifta SV and Egrifta WR labels). Neither was tested for visceral fat on its own.

Those lower numbers belong to their own vials and mixing systems, and the WR and SV formulations are not substitutable. A research vial of tesamorelin is neither, so the unit tables below carry the 2mg trial dose and the 1mg dose from the dose-ranging and cognition trials, with the two label doses alongside for comparison.

The 2005 trial is the only head-to-head comparison of doses. Over 12 weeks, 1mg raised IGF-1 by 48% and 2mg by 65%. Trunk fat fell 4.6% on 1mg and 9.2% on 2mg, and only the 2mg result separated from placebo. Visceral fat fell 3.6% on 1mg, less than the 5.4% drop on placebo, and 15.7% on 2mg (Falutz, AIDS, 2005). The phase 3 trials that followed used 2mg.

Micropipette dispensing a small measured drop of tesamorelin solution into a microtube

How many units of tesamorelin from a 10mg vial

On a U-100 syringe, 100 units is 1mL, so the units for any dose are the dose divided by the vial’s strength, times 100. With 2mL of water in a 10mg vial, the strength is 5mg per mL and 2mg is 40 units. With 2.5mL it is 4mg per mL, and 1mg lands on 25 units.

Vial and waterStrength1mg1.28mg1.4mg2mg
10mg with 1mL10mg per mL10 units13 units14 units20 units
10mg with 2mL5mg per mL20 units26 units28 units40 units
10mg with 2.5mL4mg per mL25 units32 units35 units50 units
10mg with 3mL3.33mg per mL30 units38 units42 units60 units
20mg with 2mL10mg per mL10 units13 units14 units20 units
20mg with 3mL6.67mg per mL15 units19 units21 units30 units

The 1.28mg and 1.4mg columns are rounded to the nearest whole unit. On the WR label itself, 1.28mg is 0.16mL of an 8mg-per-mL solution, which is 16 units on the same syringe. That vial is mixed far stronger than any research setting above, which is why its dose looks so small on the barrel.

Reading the syringe backwards: units to milligrams

Many researchers already have a unit number from somewhere and need the milligrams behind it. The answer changes with the water: 20 units is 2mg in a vial mixed with 1mL and 0.67mg in one mixed with 3mL. With the usual 2mL in a 10mg vial, 10 units is 0.5mg, 20 units 1mg, 40 units 2mg and 50 units 2.5mg.

How many units of tesamorelin from a 20mg vial

The 20mg vial holds twice the powder, so the same water makes it twice as strong. With 2mL it runs at 10mg per mL, and 2mg is 20 units, the same reading as a 10mg vial mixed with 1mL. With 3mL it runs at 6.67mg per mL and 2mg is 30 units.

The bigger vial changes the arithmetic more than the dose. At 2mg a day it covers ten days instead of five, and it costs $158 against $95, about $7.90 per mg against $9.50. Units for any other water volume come straight out of the reconstitution calculator.

Gloved hand adding water to a vial of white tesamorelin powder beside a 20mg vial

How much bacteriostatic water for 10mg of tesamorelin

Any volume from 1mL to 3mL gives the same milligrams; the water only decides how far the plunger travels. Two settings make the common doses land on round lines. For 2mg a day, 2mL puts the dose at 40 units. For 1mg a day, 2.5mL puts it at 25 units.

Less water means a smaller injection but a coarser scale. With 1mL in a 10mg vial each unit carries 100mcg, so one unit of misreading is 5% of a 2mg dose. With 2mL each unit carries 50mcg, and with 3mL about 33mcg. In a 20mg vial, 2mL gives the same 100mcg per unit as 1mL in a 10mg vial.

The WR label specifies bacteriostatic water for injection, the same type of diluent as Simms Research’s Research Water: sterile water with 0.9% benzyl alcohol, the preservative that lets one vial serve many doses. The SV label uses plain sterile water because its vial is mixed and used in a single sitting.

Mixing it the way the label does

Tesamorelin is a 44-amino-acid peptide, long enough to foam if the water is jetted onto the powder. The SV instructions angle the needle so the water runs down the inside wall of the vial, then roll the vial between the palms for 30 seconds without shaking. The WR label uses a gentle swirl, also without shaking. Both labels set the same finish line: a clear, colorless solution with no particles.

How long does a 10mg vial of tesamorelin last

Divide the vial by the dose. At 2mg a day a 10mg vial is five doses and a 20mg vial is ten. A 10mg vial is also seven doses at 1.4mg and ten at 1mg, and the 20mg vial doubles each. Taking weekends off moves a 10mg vial’s last dose from day 7 to day 9 at 1.4mg and from day 10 to day 12 at 1mg.

Once mixed, a tesamorelin vial is kept at 2–8°C and used within 28 days. Every combination above finishes inside that window. The tightest is the 20mg vial at 1mg five days a week, whose last dose falls on day 26. Sealed powder storage is covered in the refrigeration guide.

The labels run much shorter clocks because they are different products. SV is mixed and injected immediately, and WR is kept at room temperature and thrown out 7 days after mixing. Those limits belong to those formulations, not to a refrigerated research vial.

Down to the last unit: what the measured content changes

A vial labeled 10mg rarely holds exactly 10mg. The current batch, 2026-TN650, measured 11.11mg across three vials. Mixed with 2mL, that vial holds 200 units at 5.56mg per mL, so every unit carries a little more than the label math says.

Drawing 40 units, the label-math dose for 2mg, delivers 2.22mg five times. Drawing 36 units delivers 2.0mg and leaves a sixth partial dose of about 1.1mg in the bottom of the vial. The earlier batch, TN544, measured 10.19mg, close enough to the label that 39 units is 2.0mg.

How much tesamorelin for 8, 12 or 26 weeks

The phase 3 trials ran 26 weeks before their first readout. Shorter plans of 8 or 12 weeks are common in research protocols, and the 20-week cognition trial ran on 1mg. Vial counts round up, and prices are the current shelf prices of the Tesamorelin 10mg and 20mg vials.

PlanTotal10mg vials20mg vials
2mg daily, 8 weeks112mg12 vials, $1,1406 vials, $948
2mg daily, 12 weeks168mg17 vials, $1,6159 vials, $1,422
2mg daily, 26 weeks364mg37 vials, $3,51519 vials, $3,002
1mg daily, 12 weeks84mg9 vials, $8555 vials, $790
1mg daily, 20 weeks140mg14 vials, $1,3307 vials, $1,106

At 2mg a day the 20mg vial costs 12% to 17% less across these plans and halves the number of vials to mix. Water adds up too: 19 vials mixed with 2mL each use 38mL, four 10mL bottles.

Every day or five days a week, morning or night

Every controlled tesamorelin trial dosed seven days a week. Five days on and two off is a clinic and research convention with no trial behind it. At 2mg a dose it delivers 10mg a week, 71% of the 14mg the trials gave.

Neither label sets a time of day. The phase 3 trials gave the dose once daily without fixing the hour. The one trial that did fix it, the 2012 cognition study, injected 1mg 30 minutes before bedtime (Baker, Archives of Neurology, 2012). That choice follows the body’s own pattern, in which the largest growth hormone pulse comes early in sleep.

Tesamorelin itself is gone fast: its half-life is 8 to 11 minutes. What lasts is the response. In 13 healthy men, two weeks of 2mg a day raised mean overnight growth hormone, the size of each pulse and the baseline between pulses, and lifted IGF-1 by 181µg/L (Stanley, Journal of Clinical Endocrinology and Metabolism, 2010).

Food timing follows the same rule as every GHRH-type peptide, since a glucose load blunts the growth hormone response. The research behind that, and the meal timing, are in the CJC-1295 and ipamorelin dosage guide. The same guide covers pairing a GHRH peptide with ipamorelin.

How fast tesamorelin reduces belly fat at 2mg

Tesamorelin’s measured effect is on the fat inside the abdomen, around the organs, and on IGF-1, the hormone the liver makes in response to growth hormone. IGF-1 moves within two weeks. Visceral fat takes months, and the clearest readout is at 26 weeks.

WhenWhat was measuredResultSource
2 weeksOvernight growth hormone and IGF-1 in 13 healthy menMean overnight GH, pulse size and basal secretion all rose; IGF-1 up 181 µg/LStanley, 2010
12 weeksTrunk and visceral fat in 61 adultsTrunk fat −9.2% (placebo +0.8%); visceral fat −15.7% (placebo −5.4%); subcutaneous fat unchangedFalutz, 2005
13 weeksIGF-1 in the phase 3 trialsRaised IGF-1 already showing by this pointEgrifta WR label
26 weeksVisceral fat by CT, 816 people−18% and −14%, against +2% and −2% on placeboEgrifta WR label
26 weeksBody weight and lean massWeight −0.4kg and +0.5kg; lean mass +1.3kg and +1.2kg; trunk fat −1.0kg and −0.8kgEgrifta WR label
6 monthsLiver fat in 50 adultsNet drop of 2.9 points in liver lipid-to-water percentageStanley, 2014
52 weeksVisceral fat after a second 26 weeksHeld at 0% and −5% on tesamorelin; back up 22% and 16% after a switch to placeboEgrifta WR label
12 monthsLiver fat fraction in 61 adults37% relative drop; 35% finished under 5% liver fat, against 4% on placeboStanley, 2019

Does tesamorelin reduce subcutaneous fat?

Not in the trial data. In the 2005 study, fat under the skin of the abdomen was preserved and did not change in any group, while trunk and visceral fat fell on 2mg. The drop is concentrated in the deep abdominal fat, which is why the trials scanned it by CT rather than tracking body weight.

Why am I gaining weight on tesamorelin?

Body weight barely moves on tesamorelin. Across the phase 3 trials weight changed by −0.4kg and +0.5kg in 26 weeks, while lean mass rose about 1.2–1.3kg and trunk fat fell 0.8–1.0kg (Egrifta SV label, FDA, 2026). Lean tissue replacing fat keeps the scale flat even as the waist shrinks: waist circumference fell 3cm and 2cm.

Does fat come back after stopping tesamorelin?

Yes, the visceral fat returns. At week 26 the trials split the tesamorelin group in two. Those who kept dosing held their result, changing 0% and −5% over the next 26 weeks. Those switched to placebo saw visceral fat climb 22% and 16%, most of the way back (Egrifta label, FDA, 2010). IGF-1 fell back the same way, down 137 and 135ng/mL after the switch.

Gloved hand loading a tesamorelin sample into an LC-MS autosampler

The batch data behind every unit

Every Simms Research tesamorelin batch goes to an independent lab for identity, purity and net peptide content. The net content is the figure that feeds the unit math above.

The current batch, 2026-TN650, was tested on July 16, 2026 on three vials, which held 11.12, 10.84 and 11.36mg: 11.11mg on average, 11% over the label, at 99.546% average purity, with identity confirmed by LC-MS, endotoxin passed, heavy metals not detected and no growth on the sterility test. The earlier batch, TN544, was tested on May 5, 2026 on one vial: 10.19mg, 2% over the label, at 99.97% purity, with identity confirmed by LC-MS and endotoxin passed on two replicates.

Batch 2026-TN650 is the one used for the last-unit math above: its three vials ranged from 10.84mg to 11.36mg, an average 11% over the label. The full certificates for both batches are on the tesamorelin lab results page.

Frequently asked questions

Is 2mg of tesamorelin too much?

No. 2mg is the dose every phase 3 and liver-fat trial used for 26 to 52 weeks, and the newer labels lower the milligrams only because their formulations absorb better. The marker those trials tracked was IGF-1, which rose by about 107ng/mL at 26 weeks (Egrifta label, FDA, 2010).

Is 0.5mg of tesamorelin enough?

No trial has tested it. The lowest studied dose, 1mg, raised IGF-1 by 48% over 12 weeks but did not move visceral fat beyond placebo (Falutz, AIDS, 2005).

How long should a tesamorelin cycle be?

The trials ran 26 weeks, then a second 26. The visceral fat result held through 52 weeks of continuous dosing and faded after stopping. About half of participants developed antibodies to tesamorelin by week 26, and their visceral fat and IGF-1 responses matched those without antibodies. The WR label’s one rule on length is to reconsider continuing when visceral fat has not dropped.

How much tesamorelin should women take?

The same as men: the labels give one dose for both sexes. Women were 14% and 16% of the phase 3 participants and 89 of the 152 adults in the 1mg cognition trial.

Does tesamorelin make you retain water?

Most people don’t. Over 26 weeks on 2mg, peripheral swelling was reported by 6%, against 2% on placebo, and joint pain by 13% against 11% (Egrifta SV label, FDA, 2026). It is tied to the rise in growth hormone and was either transient or resolved after stopping.

Does tesamorelin keep you up at night?

The one trial that measured it found no change. In the 2012 cognition study, 20 weeks of 1mg at bedtime left sleep quality scores level with placebo.

Is tesamorelin approved?

Egrifta SV and Egrifta WR are prescription drugs, FDA-approved for one use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Simms Research sells tesamorelin vials for laboratory research use only.

Keep exploring

Verify the underlying batch data

Compare published methods and results, then open the source certificate for the batch you are evaluating.

Browse lab results